The World of Health & Medicine News

A specialized vitamin D3 nanoemulsion significantly improved core autism symptoms in children

A specialized vitamin D3 nanoemulsion significantly improved core autism symptoms in children

New research explores how a vitamin D3 nanoemulsion might help ease the primary symptoms of autism spectrum disorder (ASD) in young children. Many children diagnosed with ASD tend to have low levels of vitamin D3, a deficiency that has been associated with slower development in language, adaptive behaviors, and fine motor coordination.

Previous studies on regular vitamin D3 supplements have delivered inconsistent results. In contrast, this study focuses on a nanoemulsion form of vitamin D3, which is specifically designed to improve how well the body absorbs and utilizes the nutrient, potentially leading to more effective outcomes.

Study Design and Methodology

The study involved 80 children with confirmed ASD diagnoses, all between 3 and 6 years old. These children were randomly split into two groups: one group received the nanoemulsion version of vitamin D3, while the other group was given a commonly available standard supplement. Both groups followed their respective treatments for a six-month period.

Researchers evaluated the children’s vitamin D3 levels, social and adaptive behaviors, and language development both before and after the supplementation. To measure these changes, they used widely recognized assessment tools, including the Childhood Autism Rating Scale (CARS), the Vineland Adaptive Behavior Scale, and the Preschool Language Scale.

Only the nanoemulsion group showed statistically significant improvements in vitamin D3 levels, autism severity, social IQ, and both receptive and expressive language performance. The conventional supplement, despite raising blood vitamin D3 levels, did not lead to meaningful improvements in behavioral outcomes.

Implications and Future Directions

The study concludes that the nanoemulsion form of vitamin D3 is superior to the conventional oral form in terms of increasing vitamin bioavailability and producing clinically relevant improvements in children with ASD. The authors suggest that nanoemulsion technology could offer a valuable strategy for enhancing the effectiveness of nutritional interventions in neurodevelopmental disorders.

However, they acknowledge that further studies with larger sample sizes and long-term follow-up are needed to confirm these findings and explore potential gender-related differences in response.

 

spot_img

Explore more

spot_img

WHO says mpox now detected in more countries, with 17 deaths...

WHO says mpox now detected in more countries, with 17 deaths in Africa over six weeks The World Health Organization (WHO) said on Friday that...

Metsera the US obesity biotech at centre of Novo, Pfizer bidding...

Metsera the US obesity biotech at centre of Novo, Pfizer bidding war Metsera has become the obesity drug market's hottest ticket. The New York-based biotech is...

Eli Lilly says weight-loss pill a candidate for speedy approval under...

Eli Lilly says weight-loss pill a candidate for speedy approval under new US programme Eli Lilly said its experimental weight-loss pill met most criteria for...

BridgeBio surges as muscle disorder drug scores ‘best case’ trial win

BridgeBio surges as muscle disorder drug scores 'best case' trial win BridgeBio Pharma (BBIO.O), opens new tab said on Monday its experimental drug for a rare muscle...

US FDA warns four firms over unapproved fluoride drugs for children

US FDA warns four firms over unapproved fluoride drugs for children The U.S. Food and Drug Administration said on Friday it warned four companies that...

Inhibrx shares surge after bone cancer drug slows disease progression in...

Inhibrx shares surge after bone cancer drug slows disease progression in trial Inhibrx Biosciences said on Thursday its experimental drug helped slow the progression of...

Investors managing $11.5 trillion urge food companies to diversify away from...

Investors managing $11.5 trillion urge food companies to diversify away from animal proteins  Investors managing $11.5 trillion in assets are calling on major food companies...

Lilly partners with Nvidia on AI supercomputer to speed up drug...

Lilly partners with Nvidia on AI supercomputer to speed up drug development  Eli Lilly (LLY.N), opens new tab said on Tuesday it was collaborating with Nvidia (NVDA.O), opens...